Investing.com - DA Davidson has assumed coverage on Vertex Inc. (NASDAQ:VERX) with a Neutral rating and a $29.00 price target, according to a research note released Tuesday. The tax technology company ...

Treating pain has long been a challenge. Over-the-counter treatments often don’t do enough, while opioids block pain signals but can be extremely addictive. Vertex broke those barriers with Journavx, ...

Vertex Pharmaceuticals recently announced that the FDA has granted Breakthrough Therapy Designation to povetacicept for IgA nephropathy, along with key clinical advancements in its kidney disease ...

Vertex has begun a full-court press for Journavx, enlisting NBA All-Star Jayson Tatum to discuss his use of the new non-opioid painkiller while recovering from a serious injury. Tatum ruptured his ...

With the business potentially at an important milestone, we thought we'd take a closer look at Vertex, Inc.'s (NASDAQ:VERX) future prospects. Vertex, Inc., together with its subsidiaries, provides ...

The recent Vertex Pharmaceuticals Incorporated stock drop after VX-993 trial results is overblown; the pain franchise remains robust with multiple promising avenues and ongoing trials. Vertex's CF ...

Bill McColl has 25+ years of experience as a senior producer and writer for TV, radio, and digital media leading teams of anchors, reporters, and editors in creating news broadcasts, covering some of ...

Vertex reported healthy revenue in its second quarter earnings report, though news of VX-993’s mid-stage trial results and lack of alignment with the FDA regarding an expanded label for Journavx ...

If you purchase an independently reviewed product or service through a link on our website, Variety may receive an affiliate commission. When Fender reached out to Khruangbin‘s Laura Lee and Mark ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Vertex Pharmaceuticals is laying ...

Vertex Pharmaceuticals is the global leader in cystic fibrosis treatment -- and that’s set to continue thanks to the company's innovation. The company recently has expanded into another area, too, and ...